Non-racemic MDMA

Non-racemic MDMA, also known by the developmental code names ALA-002 and AM-1002, are non-racemic mixtures of the MDMA (midomafetamine; "ecstasy") enantiomers (R)-MDMA and (S)-MDMA which are under development for the treatment of social phobia (social anxiety disorder; SAD), autistic spectrum disorder (ASD), and generalized anxiety disorder (GAD).^[1][2][3] ALA-002, which is under development by PharmAla Biotech for social phobia and autistic spectrum disorders, is a mixture of 70–80% (R)-MDMA and 20–30% (S)-MDMA.^[1][4] Conversely, AM-1002, which is under development by Arcadia Medicine for GAD, is a mixture of 90% (R)-MDMA and 10% (S)-MDMA.^[5] Based on animal studies, (R)-MDMA-preferring non-racemic MDMA mixtures show less hyperlocomotion, hyperthermia, hypertension, and neurotoxicity than racemic MDMA.^[5][6] ALA-002 is in phase 2 clinical trials for SAD and ASD as of 2026, whereas AM-1002 is in phase 1/2 trials for GAD as of 2026.^[1][2][7] Jupiter Neurosciences acquired the exclusive rights to develop ALA-002 in the United States from PharmAla Biotech in May 2026.^[8]

(R)-MDMAEntactogen; Serotonin–norepinephrine releasing agent (SNRA)

(S)-MDMAEntactogen; Serotonin–norepinephrine–dopamine releasing agent (SNDRA)

Other namesNon-racemic midomafetamine; Non-racemic ecstasy; ALA-002; ALA002; ALA-02; ALA02; AM-1002; AM1002

Quick facts Combination of, (R)-MDMA ...

Non-racemic MDMA

(R)-MDMA (top) and (S)-MDMA (bottom)
Combination of
(R)-MDMA	Entactogen; Serotonin–norepinephrine releasing agent (SNRA)
(S)-MDMA	Entactogen; Serotonin–norepinephrine–dopamine releasing agent (SNDRA)
Clinical data
Other names	Non-racemic midomafetamine; Non-racemic ecstasy; ALA-002; ALA002; ALA-02; ALA02; AM-1002; AM1002

Close